The World Health Organization has drawn up a list of the 12 resistant bacteria most problematic to human health—and called on governments and industry to step up efforts to find new medicines to fight them.
A new survey of U.S. scientists, FDA researchers and biomedical clinicians has found that most are concerned over FDA Commissioner nominee Scott Gottlieb’s long list of ties to biopharmas, with the majority also believing that proposed cuts to the National Institutes of Health (NIH) would hurt drug discovery.
It has been said over and over by Pharma execs forced to defend high prices: A complex, opaque pricing and distribution system in the U.S. has helped drive up drug costs. Now, a new report commissioned by industry group PhRMA lends statistics to that argument.
Representatives from the biotechnology, medical device and generic drug industries told members of the Senate Committee on Health, Education, Labor & Pensions on Tuesday, April 4, 2017 that if the five-year user fee programs are not reauthorized, the US Food and Drug Administration (FDA) would likely see more than 3,000 job cuts.
The US Food and Drug Administration’s (FDA) Office of Regulatory Affairs (ORA), which carries out the agency’s inspection program, will officially begin a major overhaul in the coming weeks, according to FDA’s Center for Devices and Radiological Health (CDRH) Director Jeffrey Shuren.
Scott Gottlieb’s close links to the pharma industry have threatened to undermine his chances of becoming FDA commissioner—but he thinks he has a solution.